All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions DRUG UPDATES

ALL Types

2023-12-04T12:33:56.000Z

ASH 2023 abstracts: What’s hot in ALL?

By Quintina Dawson, Megan Kelly

Dec 4, 2023

Bookmark this article

To help navigate the exciting content being presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL

419	RPT1G: A 1st-in-class small molecule NAMPT inhibitor as a novel therapeutic for acute lymphocytic leukemia
517	Risk-adjusted therapies yield equivalent outcomes for adolescents and young adults (AYAs) treated for newly diagnosed t-cell acute lymphoblastic leukemia (t-all) on Children’s Oncology Group (COG) studies AALL0434 and AALL123
823	Outcome of infants treated on total therapy for infants with acute lymphoblastic leukemia I: results from a non-randomized multi-center study
824	Patients with down syndrome and high-risk B-acute lymphoblastic leukemia demonstrate improved outcomes on a modified chemotherapy regimen: a report from Children’s Oncology Group study AALL1131
825	Pediatric patients with high-risk b-cell all in first complete remission may benefit from less toxic immunotherapy with blinatumomab – results from randomized controlled phase 3 trial AIEOP-BFM all 2017
826	Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult ph- b-lineage acute lymphoblastic leukemia. Final results of the phase II gimema LAL2317 trial
827	Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: early results from a phase II study
828	CNS irradiation in adult de novo B-precursor ALL / LBL: results of the randomized GMALL trial 08/2013 indicate potential antileukemic efficacy
891	Dasatinib and CAR-T cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults
961	Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class fusion B-all): Children’s Oncology Group AALL1131
962	Frontline consolidation with nelarabine for adults with high-risk t-cell acute lymphoblastic leukemia. Results of the GRAAII-2014/T Atriall phase 2 study
963	Nelarabine (nel), pegylated asparginase (peg) and venetoclax (ven) incorporated to HCVAD chemotherapy in the frontline treatment of adult patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/T-LBL)
964	Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial
1498	Efficacy and safety of recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): complete follow-up of the Children’s Oncology Group (COG) AALL1931 study
1499	Long-term follow up for SWOG 1318: combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
1500	Impact of high-risk cytogenetics (HR-CTG) on the outcome of newly diagnosed adult patients with Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) treated with frontline blinatumomab (blina ) and/or inotuzumab ozogamicin (ino ) containing hypercvad (HCVAD) therapy
1504	Frontline combination of 3rd generation TKI olverembatinib and blinatumomab for Ph+/Ph-like all patients
1510	Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: primary endpoint results from the Blissphall study
1512	A phase i/ii study to investigate the addition of venetoclax to dasatinib and steroids in patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): the Venda Trial, in progress
2827	Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia: updates from a phase II trial
2868	A phase ii study of low-intensity chemotherapy (mini-hyper-cvd) and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
2869	Venetoclax combined with hag regimen in newly diagnosed ETP-ALL: interim analysis of a prospective, multicenter, phase 2 trial
2870	A phase 1 study of venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with B-cell Ph-like ALL
2871	Ponatinib versus imatinib in patients with newly diagnosed Ph+ all: subgroup analysis of the phase 3 Phallcon study
4205	Combination of olverembatinib and vp regimen as first-line therapy for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
4238	Updated results on a multicenter phase II study of a dose intensified pediatric regimen in adults with acute lymphoblastic leukemia: the 06-254 DFCI ALL consortium trial
4243	Reduced-dose chemotherapy followed by blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study
4245	Updated results from a phase II study of hyper-cvad, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia
4249	Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALLL2820 trial
4250	Long-term results of the frontline dasatinib/blinatumomab protocol (d-alba, Gimema LAL2116) for adult Ph+ acute lymphoblastic leukemia

Treatment for relapsed/refractory ALL

770	Phase 1/2 dose-escalation/dose-expansion study of anti-cd7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (r/r) t-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma (T-ALL/LBL)
889	Efficacy and safety of interleukin-6-knockdown CD19-targeted CAR T cells(ssCART-19) for relapsed/refractory B-ALL
966	Blinatumomab in combination with immune checkpoint inhibitors (icis) of PD-1 and CTLA-4 in adult patients with relapsed/refractory (r/r) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study
1501	Venetoclax combined with azacitidine was effective and safe for relapsed/refractory T-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial
1502	Venetoclax and blinatumomab for adult patients with relapsed/refractory or mrd positive Ph-negative B-precursor all: first results of the GMALL-Bliven trial
1509	A phase I study of venetoclax in combination with inotuzumab ozogamicin for relapsed or refractory all in adults
2872	Results from the phase 1 portion of a trial of oral ixazomib combined with chemotherapy in relapsed/refractory acute lymphoblastic leukemia or lymphoma in children, adolescents and young adults: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
3474	First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, b-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics
3485	A multicenter study of CAR-T cell therapy for relapse of B-ALL post allogeneic stem cell transplantation
3491	Efficacy and safety of the second CAR-T therapy in patients with refractory/relapsed acute B-cell lymphoblastic leukemia
4242	A phase 1 study of CD38-bispecific antibody (XmAB18968) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia
4847	Updated results of the phase I BALLI-01 trial of ucart22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (r/r) cd22+ b-cell acute lymphoblastic leukemia (B-ALL)
Lba-5	Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study

Allogeneic transplantation

232	Comparable outcome after busulfan- or treosulfan-based conditioning regimen in children above 4 years of age with all undergoing allogeneic hsct. Results from the Prospective International Forum-Trial
233	Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation (allo-SCT) for relapsed CD22 (+) lymphoid malignancies: long-term survival results
234	Short-term blinatumomab as a bridge therapy for hematopoietic stem cell transplantation in B-cell acute lymphoblastic leukemia with low leukemia burden
239	Cd7 chimeric antigen receptor T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation remarkably improved long-term disease-free survival in refractory/relapsed T-cell acute lymphoblastic leukemia/lymphoma
1461	Role of allogeneic stem cell transplantation in preventing relapse in adult BCR::ABL1-like acute lymphoblastic leukemia
2210	Incidence and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia
2234	How much have post-transplant outcomes improved since 2000 for patients with Philadelphia-positive acute lymphoblastic leukemia in first remission? A study from the EBMT Acute Leukemia Working Party
2235	Allogeneic hematopoietic stem cell transplantation for elderly acute lymphoblastic leukemia patients: a registry study from the société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC)
2237	Prognostic factors impacting post-transplant outcomes in adult t-cell acute lymphoblastic leukemia: a registry-based study by the EBMT Acute Leukemia Working Party
2830	Clinical outcomes of adults undergoing allogeneic stem cell transplant for secondary acute lymphoblastic leukemia
4958	Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the Adult Acute Lymphoblastic Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy

Real-world evidence

1029	Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (r/r) adult b-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR Registry
1030	Brexucabtagene autoleucel in adults with relapsed/refractory B-cell all: outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult all (ROCCA)
1507	Use of ponatinib alone or combined with other therapies in relapsed/refractory Ph-like acute lymphoblastic leukemia. A campus all real-life study
3498	Efficacy and tolerance of brexucabtagene autoleucel in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia : a Graall study from the Descar -T Registry

Socioeconomic challenges

493	Racial/ethnic disparity for hematologic malignancies in different healthcare systems in the U.S
671	The impact of social determinants of health on brexucabtagene autoleucel outcomes in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
1468	Socioeconomic determinants and the biology and outcomes of acute lymphoblastic leukemia in adults
2391	Socioeconomic disadvantage is associated with decreased long-term survival in adolescent and young adult patients with acute lymphoblastic leukemia
2392	Distance to care predicts clinical trial enrollment on COG ALL clinical trials: a report from the Children’s Oncology Group
5169	Disparities among adolescent and young adult patients with acute lymphoblastic leukemia
5078	Enhanced support services including nurse navigation mitigate socioeconomic disparities in the treatment of patients with acute lymphoblastic leukemia

Molecular biomarkers

495	Risk factors for CD19-targeting CAR T manufacturing failure and patient outcomes: a report from the UK National CAR T Panel
521	Association between high antimetabolite dose intensity during maintenance, toxicities and relapse risk in children with acute lymphoblastic leukemia (ALL): COG-AALL03N1 report
841	Single cell transcriptomic analysis of B-cell acute lymphoblastic leukemia (B-all) reveals correlation between leukemia cell state, genetic alterations and clinical outcome
844	NGS-based stratification refines the risk stratification in T-ALL and identifies a very high-risk subgroup of patients
1464	Achievement of undetectable BCR::ABL1 (UBCR::ABL1) is predictive of improved survival in Philadelphia chromosome positive (Ph+ve ) acute lymphoblastic leukemia (ALL) patients not receiving allogeneic stem cell transplantation
2134	Low disease burden pre-CAR T-cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy
2969	Inflammatory signatures define a new high-risk T-lineage ALL subtype
2970	Genomic determinants of therapy response in ETV6::RUNX1 leukemia
2975	Drug response profiling of childhood T-cell acute lymphoblastic leukemia to inform functional precision medicine
4346	The CNS microenvironment promotes leukemia cell survival by disrupting tumour suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia
4349	Exploring the heterogeneity of response to blinatumomab in high-risk philadelphia-negative B-cell precursor acute lymphoblastic leukemia: an analysis from the quest sub-study of the Graall-2014/B trial
4350	Drug response profiling informs personalized bridging to cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia

Treatment-related toxicities

522	Toxicity profile of brexucabtagene autoleucel (brexu-cel; cd19-directed CAR T-cell therapy) in adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL): results from a multicenter real-world outcomes study
1456	Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen
1459	Hepatitis b reactivation without hepatitis is a common event in adolescent/adult patients of acute lymphoblastic leukemia with occult hepatitis b (OHBI) treated on pediatric protocols and warrants prophylactic antivirals: a prospective cohort study
2873	Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

Others

127	A machine learning approach for predicting the occurrence of asparaginase-associated pancreatitis in pediatric patients with acute lymphoblastic leukemia
132	Development of a real-time dashboard characterizing acute leukemia clinical trial enrollment diversity at the practice, investigator, and individual clinician level
257	Excellent safety profile of a low-cost novel humanized cd19 CAR T-cell therapy, actalycabtagene autoleucel: potential impact on access and feasibility
417	Phenotypic drug response profiling identifies asparaginase-based synergistic combinations for very high risk acute lymphoblastic leukaemia
887	A rare cell state underpins diverse mechanisms of adaptive resistance to CAR T-cell therapy in B-cell acute lymphoblastic leukemia
3475	Role of microenvironment in influencing the activity of CD19 CAR T cells in B-cell precursor acute lymphoblastic leukemia (B-ALL)
3704	Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: a retrospective study across diverse US practices
3760	Trends of obesity over time and its prognostic significance in children and adolescents with newly-diagnosed acute lymphoblastic leukemia in Canada: a population-based study

ASH 2023 abstracts

To download this document, click below.

Download here

More about...

Add bookmark

What are the challenges of sequencing immunotherapies in adults with ALL?

During the 2023 Society of Hematologic Oncology Congress (SOHO), the ALL Hub spoke to Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, What are the challenges of...

Oct 27, 2023

Add bookmark

What are the challenges of sequencing immunotherapies in adults with ALL?

During the 2023 Society of Hematologic Oncology Congress (SOHO), the ALL Hub spoke to Bijal Shah, Moffitt Cancer Center,...

Oct 27, 2023

Add bookmark

Association of BMI on outcomes in adolescent and young adult patients with ALL

This article summarizes a study by Shimony et al. describing the association between BMI and toxicities and survival among adolescents and young adults with ALL.

Oct 10, 2023

Add bookmark

Association of BMI on outcomes in adolescent and young adult patients with ALL

This article summarizes a study by Shimony et al. describing the association between BMI and toxicities and survival...

Oct 10, 2023

Subscribe to get the best content related to ALL delivered to your inbox

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2023 abstracts: What’s hot in ALL?

By Quintina Dawson, Megan Kelly

Dec 4, 2023

Frontline and emerging therapies for ALL

Treatment for relapsed/refractory ALL

Allogeneic transplantation

Real-world evidence

Socioeconomic challenges

Molecular biomarkers

Treatment-related toxicities

Others

More about...

Related articles

Oct 27, 2023

Oct 27, 2023

Oct 10, 2023

Oct 10, 2023

Newsletter